Australian Clinical Labs And 2 Other ASX Penny Stocks To Consider

Simply Wall St.07-17 10:04

The Australian stock market is facing a slight downturn, with tech sector challenges on Wall Street influencing the ASX 200 and contributing to a cautious outlook. Despite these broader market ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2652472571?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/2053000-choice1-main-header/1585186555515","is_english":true,"pubTime":"2026-07-17 10:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2652472571","market":"sg","top_or_hot":-1,"title":"Australian Clinical Labs And 2 Other ASX Penny Stocks To Consider","media":"Simply Wall St.","content":"<div>\n<p>The Australian stock market is facing a slight downturn, with tech sector challenges on Wall Street influencing the ASX 200 and contributing to a cautious outlook. Despite these broader market ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/materials/asx-hmx/hammer-metals-shares/news/australian-clinical-labs-and-2-other-asx-penny-stocks-to-con\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Australian Clinical Labs And 2 Other ASX Penny Stocks To Consider</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAustralian Clinical Labs And 2 Other ASX Penny Stocks To Consider\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-17 10:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/au/materials/asx-hmx/hammer-metals-shares/news/australian-clinical-labs-and-2-other-asx-penny-stocks-to-con><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Australian stock market is facing a slight downturn, with tech sector challenges on Wall Street influencing the ASX 200 and contributing to a cautious outlook. Despite these broader market ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/materials/asx-hmx/hammer-metals-shares/news/australian-clinical-labs-and-2-other-asx-penny-stocks-to-con\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GEAR.AU","symbol_name":"BETASHARES GEARED AUS EQTY F","start_time":0,"source_url":"https://simplywall.st/stocks/au/materials/asx-hmx/hammer-metals-shares/news/australian-clinical-labs-and-2-other-asx-penny-stocks-to-con","article_id":"2652472571","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/2053000-choice1-main-header/1585186555515"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-hmx/hammer-metals-shares/news/australian-clinical-labs-and-2-other-asx-penny-stocks-to-con","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2652472571","pubTimestamp":1784253898,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"The Australian stock market is facing a slight downturn, with tech sector challenges on Wall Street influencing the ASX 200 and contributing to a cautious outlook. Despite these broader market tensions, investors continue to seek opportunities in penny stocks, which can offer unique value propositions. Although often associated with smaller or newer companies, penny stocks can present compelling opportunities for those looking to uncover financial strength and potential growth beyond the more...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"GEAR.AU":"BETASHARES GEARED AUS EQTY F","BEAR.AU":"BETASHARES AUS EQ BEAR HF","XKO.AU":"标普/澳交所 300指数","QFN.AU":"BetaShares Australian Fincls Sect ETF","DACE.AU":"DIMENSIONAL AUST CORE EQ","GIVE.AU":"PERPETUAL ESG AU SHR EQMF","BK7095":"多种金属与采矿","ZYAU.AU":"Etfs S&p/asx 300 High Yield Plus Etf","BK7104":"黄金","ACL.AU":"Australian Clinical Labs Ltd","E200.AU":"SPDR S&P/ASX 200 ESG FUND","IOZ.AU":"iShares Core S&P/ASX 200","VAP.AU":"VANGUARD AU PROP SEC IDX ETF","QRE.AU":"BetaShares Australian Res Sect ETF","VAS.AU":"VANGUARD AUST SHARES IDX ETF","OZF.AU":"SPDR S&P/ASX 200 FINANCIALS","STW.AU":"SPDR® S&P/ASX 200 ETF","OZR.AU":"SPDR S&P/ASX 200 RESOURCES F","BK7124":"保健护理服务","IMLC.AU":"INV MUTUAL CONC AUS SHAR ETF","IIGF.AU":"Intelligent Investor Australian Equity Growth Fund (Managed Fund)","BBOZ.AU":"BETASHARES AUSTRALIAN STRONG BEAR (HEDGE FUND)","SLF.AU":"SPDR S&P/ASX 200 LISTED PROP","EIGA.AU":"EINVEST INCOME GENERATOR FD","IISV.AU":"INTELL INV SELVAL SHR FD MF","XAO.AU":"标普/澳交所 普通股指数","HMX.AU":"HAMMER METALS LTD","XJO.AU":"标普/澳交所 200指数","PLA.AU":"PACIFIC LIME AND CEMENT LIMITED"},"translate_title":"澳大利亚临床实验室和其他 2 只值得考虑的澳大利亚证券交易所细价股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SLF.AU":0.6,"EIGA.AU":0.6,"DACE.AU":0.6,"VAP.AU":0.6,"HMX.AU":1,"XJO.AU":1.5,"BEAR.AU":0.6,"GEAR.AU":0.6,"BBOZ.AU":0.6,"VAS.AU":0.6,"PLA.AU":1,"XKO.AU":1.5,"IOZ.AU":0.6,"IIGF.AU":0.6,"OZR.AU":0.6,"ACL.AU":1,"ZYAU.AU":0.6,"E200.AU":0.6,"OZF.AU":0.6,"GIVE.AU":0.6,"XAO.AU":1.5,"QRE.AU":0.6,"STW.AU":0.6,"IMLC.AU":0.6,"IISV.AU":0.6,"QFN.AU":0.6},"content_text":"The Australian stock market is facing a slight downturn, with tech sector challenges on Wall Street influencing the ASX 200 and contributing to a cautious outlook. Despite these broader market tensions, investors continue to seek opportunities in penny stocks, which can offer unique value propositions. Although often associated with smaller or newer companies, penny stocks can present compelling opportunities for those looking to uncover financial strength and potential growth beyond the more established names.Below we spotlight a couple of our favorites from our exclusive screener.AdvertisementAustralian Clinical Labs (ASX:ACL)Simply Wall St Financial Health Rating: ★★★★☆☆Overview: Australian Clinical Labs Limited offers pathology diagnostic services in Australia and has a market cap of A$447.11 million.Operations: The company's revenue primarily comes from its Pathology/Clinical Laboratory Services segment, generating A$737.89 million.Market Cap: A$447.11MAustralian Clinical Labs Limited, with a market cap of A$447.11 million, has shown resilience in its financial structure despite challenges. The company maintains a satisfactory net debt to equity ratio of 32.5% and its interest payments are well covered by EBIT at 4.9 times coverage. However, ACL faces hurdles as short-term assets (A$115.5M) do not cover short-term liabilities (A$196.9M), and profit margins have declined from 4.2% to 3.6%. Recent leadership changes include the appointment of Greg Horan as Group CEO and Dr Amandeep Hansra as a non-executive director, potentially steering strategic growth initiatives forward.Get an in-depth perspective on Australian Clinical Labs' performance by reading our balance sheet health report here.Assess Australian Clinical Labs' future earnings estimates with our detailed growth reports.ASX:ACL Revenue & Expenses Breakdown as at Jul 2026Hammer Metals (ASX:HMX)Simply Wall St Financial Health Rating: ★★★★☆☆Overview: Hammer Metals Limited is an Australian company focused on the exploration and extraction of mineral resources, with a market cap of A$60.71 million.Operations: The company generates its revenue of A$0.26 million from operations in Australia.Market Cap: A$60.71MHammer Metals Limited, with a market cap of A$60.71 million and minimal revenue of A$0.26 million, is pre-revenue and debt-free, highlighting its speculative nature typical of penny stocks. The company has managed to reduce losses over the past five years by 17.6% annually but remains unprofitable with high weekly volatility at 14%. Recent developments include acquisition interest from Austral Resources Australia Ltd for A$71.4 million and Larvotto Resources Limited for A$54 million, both subject to shareholder approval and regulatory conditions, indicating potential shifts in ownership that could impact future operations and strategic direction.Take a closer look at Hammer Metals' potential here in our financial health report.Evaluate Hammer Metals' historical performance by accessing our past performance report.ASX:HMX Debt to Equity History and Analysis as at Jul 2026Pacific Lime and Cement (ASX:PLA)Simply Wall St Financial Health Rating: ★★★★☆☆Overview: Pacific Lime and Cement Limited (ASX:PLA) is an investment holding company focused on the exploration and evaluation of mineral resources, with a market capitalization of A$335.65 million.Operations: No specific revenue segments are reported for Pacific Lime and Cement Limited.Market Cap: A$335.65MPacific Lime and Cement Limited, with a market cap of A$335.65 million, is pre-revenue and unprofitable but has reduced its losses by 20.5% annually over five years. The company trades significantly below its estimated fair value, suggesting potential for appreciation if conditions improve. Recent executive changes include the appointment of Darren Holley as Chief Commercial Officer and COO, signaling a strategic focus on project execution and growth initiatives. Despite having more cash than debt and sufficient short-term assets to cover liabilities, the company faces challenges in profitability with a negative return on equity of -6.68%.Click to explore a detailed breakdown of our findings in Pacific Lime and Cement's financial health report.Review our growth performance report to gain insights into Pacific Lime and Cement's future.ASX:PLA Debt to Equity History and Analysis as at Jul 2026Make It HappenDiscover the full array of 405  ASX Penny Stocks right here.Seeking Other Investments? AI is about to change healthcare. These 127 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.  This article by Simply Wall St is general in nature. We provide commentary based on historical data \n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your \n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data. \n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. \n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2652472571","isCrawlerRequest":true}